Conditions: Perennial Allergic Rhinitis
Keywords: Perennial allergic rhinitis allergic rhinitis ciclesonide
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 824
Healthy volunteers: no

Brief summary:
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.

Detailed description:
This is a 6-month multi-center, open-label, long-term safety extension study in subjects who have completed Study 060-633 (NCT00953147). This study is designed to evaluate the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR). This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Arms:
arm 1: ciclesonide HFA 160 μg once daily

Interventions: intervention 1: ciclesonide HFA 160 μg
Intervention descriptions: intervention 1: ciclesonide HFA 160 μg once daily

Protocol document: